Stryker (NYSE:SYK) Stock Price Target Lowered at Citizens Jmp

Stryker (NYSE:SYK) had its price objective reduced by Citizens Jmp from $400.00 to $390.00 in a report published on Friday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the medical technology company’s stock.

A number of other analysts have also recently issued reports on SYK. Needham & Company LLC reduced their price objective on shares of Stryker from $418.00 to $359.00 and set a “buy” rating for the company in a research note on Friday. Canaccord Genuity Group cut Stryker from a “buy” rating to a “hold” rating and lowered their price target for the stock from $385.00 to $300.00 in a report on Friday. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, BMO Capital Markets restated an “outperform” rating and set a $317.00 price objective on shares of Stryker in a research report on Wednesday, September 9th. Sixteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $355.84.

Stryker Stock Performance

NYSE:SYK opened at $291.56 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a 50-day simple moving average of $292.83 and a two-hundred day simple moving average of $324.51. The firm has a market capitalization of $111.83 billion, a PE ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78. Stryker has a 52-week low of $267.00 and a 52-week high of $389.33.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.83%. The company’s revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.19 earnings per share. Analysts forecast that Stryker will post 14.93 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date was Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Insider Activity

In other Stryker news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda Stryker sold 300,000 shares of Stryker stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

Several large investors have recently modified their holdings of the business. Amundi lifted its holdings in Stryker by 18.3% during the second quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after buying an additional 192,447 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Stryker by 8.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after buying an additional 65,333 shares in the last quarter. Veritas Asset Management LLP bought a new position in shares of Stryker during the 2nd quarter worth approximately $168,057,000. Bank of America Corp DE acquired a new stake in Stryker in the second quarter valued at approximately $1,404,284,000. Finally, Rakuten Investment Management Inc. acquired a new stake in Stryker in the second quarter valued at approximately $18,646,000. Institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.